EUPRAXIA PHARMACEUTICALS INC. Foreign Income Tax Expense (Benefit), Continuing Operations
EUPRAXIA PHARMACEUTICALS INC. (EPRX) reported Foreign Income Tax Expense (Benefit), Continuing Operations of $19.09 thousand for the 12-month period ending 2025-12-31, per its 40-F filed 2026-03-13.
Financial Statements › Expense Statement › Income Tax
us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations · last filed 2026-03-13
| Period end | Foreign Income Tax Expense (Benefit), Continuing Operations 12 month |
|---|---|
| 2025-12-31 | $19.09K 40-F · filed 2026-03-13 |
| 2024-12-31 | $1.80K 40-F · filed 2026-03-13 |
| 2023-12-31 | $36.42K 40-F · filed 2025-03-20 |
| 2022-12-31 | $0.00 40-F · filed 2024-04-01 |